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We have previously reported that 20 hours' preincubation of human bone marrow cells with interleukin-I@ (IL-1) can protect early progenitor cells from Chydroperoxycyclophosphamide (CHC) cytotoxicity. Since tumor necrosis factoralpha (TNFa) shares many of the biologic properties of IL-I, we have compared the protective effects of TNFa with IL-1 against CHC. Incubation of human bone marrow mononuclear cells or an enriched progenitor population for 20 hours with either TNFa or IL-1 resulted in the survival of an increased number of single-and mixed-lineage colonies, including replatable blast cell colonies, while only rare colonies were seen in the control group. Antibodies to TNFa completely abolished the protection observed with IL-1, while antibodies to IL-la and IL-I@ decreased but did not abolish the protection seen with TNFa. Combinations of low doses of TNFa and IL-I showed synergy in their protective effects. Furthermore, no protection was ob-ITH THE SUCCESSFUL cloning and purification of tumor necrosis factor-alpha (TNFa) and interleukin-1 (IL-1), a great amount of data regarding their structure and functions have been generated in the last few years. Although the primary amino-acid sequence of both factors demonstrates no sequential or structural homologies,'-6 there are many similarities between their physical properties and their biological activities, and they act through different receptors. These similarities are well reviewed in several recent article^.^.^ Interestingly, both TNFa and IL-1 can induce their own synthesis as well as that of the other ~ytokine.".'~
In recently reported studies, both IL-1 and TNFa were shown to increase the survival of lethally irradiated mice, and both together showed an additive effect in their radiopr~tection.'~ TNFa was also reported to enhance the recovery of peripheral blood counts with a concomitant increase in the number of day 14 spleen colony-forming units (CFUs) as compared with controls in sublethally irradiated mice. 16 We have recently reported that in vitro preincubation with IL-1 is able to protect early, human, hematopoietic progenitor cells from the toxicity of lethal doses of 4-hydroperoxycyclophosphomide (4-HC), an active derivative of cyclophosphamide." 4-HC is used clinically to purge bone marrow patients undergoing autologous bone-marrow transplantation. The mechanism for such protection is not yet known. Since 1L-1 was shown to induce the production of a number of cytokines, including TNFa, from different accessory cell^,'^^'^^^^ we have addressed the question of whether the protection seen by IL-1 preincubation is a direct effect of IL-1 or whether IL-1 acts indirectly through the production of another cytokine (ie, TNFa). We have previously observed that neither interleukin-3 (IL-3) nor interleukin-6 (IL-6) has any role in the protection of early progenitor cells from 4-HC.26 In the present study we have shown that in addition to IL-1, TNFa is another factor capable of protecting early hematopoietic progenitor cells, including replatable, blast colony-forming cells, from 4-HC. We have also served by IL-1 , IL-1 bone-marrow-conditioned medium (IL-I -BMCM), or TNFa for HL-60. K562. KG1 , KGI a, and DU.528 leukemic-cell lines or primary acute myelogenous leukemic (AML) blast cells from the lethal effects of CHC. In the case of HL-60 and KGla cell lines, TNFa preincubation resulted in increased cytotoxicity. Furthermore, preincubation of a mixture of AML cells and normal bonemarrow cells with IL-I + TNFa before CHC resulted in the protection of normal but not leukemic progenitors. These results suggest that TNFa is necessary for the protection of normal, early, human hematopoietic progenitors from CHC, while IL-1 is not mandatory but will synergize with TNFa to offer increased protection. In addition, no protection from CHC is observed by TNFa, IL-1, or IL-I-BMCM for primary leukemic blast cells or leukemic cell lines. 0 1990 by The American Society of Hematology.
investigated the involvement of TNFa in the protection seen by IL-1 and have evaluated the protective effects of IL-1 and TNFa for normal hematopoietic cells in comparison to leukemic blast cells.
MATERIALS AND METHODS
Recombinant human IL-10 (specific activity >2 x lo7 U/mg) as well as polyclonal rabbit antibodies to human IL-la and IL-lS were generously supplied by Dr C.A. Dinarello (Boston, MA). These antibodies showed no crossreactivity with other cytokines, including TNFaZ7 Recombinant human TNFa (specific activity 2.4 x lo7 U/mg) as well as polyclonal rabbit antibody to TNFa were gifts from Dr Leo Linn, Cetus Corp (Emeryville, CA). The TNFa antibody was shown previously to have no cross-reactivity with IL-1 .27.28 Recombinant human IL-3 (specific activity 2.3 x lo6 U/mg) was received as a generous gift from Dr S. Clark, Genetics Institute (Boston, MA). Tissue-culture erythropoietin (TC-Epo; specific activity > 10,000 U/mg) was obtained from Amgen (Thousand Oaks, CA). Conditioned medium from the human bladder carcinoma cell line 5637 (5637-CM) was prepared in our laboratory as previously described."
After obtaining informed consent, bone marrow samples were aspirated from the posterior iliac crest of healthy adult volunteers and placed in tissue culture tubes containing 400 U preservative-free heparin. Mononuclear cells were obtained after centrifugation over Ficoll-Hypaque (FH) (Pharmacia, Upsala, Sweden) for use in our experiments. An enriched population of early hematopoietic progenitors was also used in some Hematopoietic growth factors.
Source of human bone marrow.
experiments. This purified cell population was obtained by introducing the post FH mononuclear cells to elutriation centrifugation containing a Sanderson Chamber and operating at 867g.29 With increasing flow rates, three fractions of cells based on cell size were collected. The second fraction, which contains the majority of hematopoietic progenitor cells, was further subjected to negative selection by labeling the cells with a panel of monoclonal antibodies (MoAbs), as previously de~cribed,~' followed by the addition of goat antimouse IgG-coated immunomagnetic microspheres. After removal of labeled cells with a magnet, the remaining cells contain an enriched population of hematopoietic progenitors with a plating efficiency of 10% to 20%. All bone marrow cells were kept frozen at -7OOC before use.
Leukemic cells. Four human leukemic cell lines were obtained from the American Type Cell Collection (ATCC): HL-60, K-562, KGI, and KGla. HL-60 and K562 leukemic cell lines were maintained in suspension culture in RPMI 1640 with 10% fetal bovine serum (FBS; Hyclone) and KGI and KGla in Iscove's modified Dulbecco medium (IMDM) with 20% FBS. Another human lymphohematopoietic stem-cell line was obtained from Dr J. Kurtzberg, Duke University Medical Center (Durham, NC) and was maintained as described previously" in RPMI 1640 supplemented with 10% horse serum and 10% heat-inactivated FBS, I mmol/L pyruvate and 2 mmol/L glutamine. All of the above cell lines were kept under an atmosphere of 5% C02 in air at 37OC and were used in the logarithmic phase of growth for the experiments described below. Peripheral blood was obtained from newly diagnosed, untreated AML patients with informed consent. These included M1, M2, M3, and M5 types based on the French-AmericanBritish (FAB) classifi~ation.~~ Mononuclear cells with greater than 90% AML blasts were separated using FH and kept frozen at -7OoC as described previo~sly.~~ Incubations. All samples were preincubated for 20 hours as previously Briefly, post-FH normal mononuclear cells (5 x IO5 cells/mL) or an enriched population of hematopoietic progenitors (1.5 x IO5 cells/mL) were incubated for 20 hours at 37OC in a 5% CO, humidified atmosphere in the presence of 50 to 100 ng/mL IL-I, 25 to 2500 ng/mL TNFa, IL-1 with 15 pL antibody to TNFa (1:70 dilution, which will neutralize greater than 250 ng/mL TNFa), TNFa with 200 ng/mL antibody to IL-la and IL-la (1:50 dilution), and as controls culture medium alone or IL-1 or TNFa with nonspecific rabbit IgG. Studies to evaluate synergy between TNFa and IL-I were performed by incubating bone marrow cells with suboptimal concentrations of IL-I (10 ng/mL) and TNFa (0.1 to 1.0 ng/mL). The incubations were performed in polypropylene-coated tubes in an upright position. Each tube contained 4 to 5 mL of mononuclear cell suspension or 1 mL of enriched cell suspension in a-MEM culture medium supplemented with 6% FBS. To assay for any effect on colony-forming cells (CFCs) within the 20-hour preincubation period, bone marrow cells from each different situation were cultured ( IO4 cells/mL/dish from bone marrow mononuclear cells and IO3 cells/mL/dish from the enriched bone marrow cell population) using the same assay as described below. Leukemic cells ( 5 x lo5 cells/mL) were incubated in a similar manner in the presence of 25 ng/mL TNFa, 50% IL-la (100 ng/mL) bone-marrow-nditioned medium (IL-I-BMCM), 100 ng/mL IL-la, or medium alone.
4-Hydroperoxycyclophosphamide. 4-HC powder was obtained from Dr M.O. Colvin, Johns Hopkins Oncology Center (Baltimore, MD). Fresh 4-HC solution in a-MEM was prepared each time just before use. A dose-response curve for 4-HC was determined for each bone marrow in advance of each experiment as follows. After 20 hours of incubation in culture medium without added growth factors, different doses of 4-HC (0 to 120 pg/mL) were added and the incubation continued for an additional 30 minutes at 37OC. The cells were then washed twice with chilled culture medium to remove the 4-HC and cultured in semisolid medium for the growth of hematopoietic CFCs. Colonies were scored weekly for 3 weeks, and the lethal dose was determined as that dose that kills all CFCs except for a few small macrophage colonies. A second sample of the same bone marrow was thawed and incubated with or without the growth factors as described above for 20 hours followed by a 30-minute incubation with the predetermined lethal dose of 4-HC. The cells were then washed twice and cultured using the colony assay as described below. Leukemic cells were treated similarly except that a dose response with 4-HC was performed for each experiment.
After the 20-hour incubation with or without IL-1/3 or TNFa, 50 to 100 pg/mL 4-HC was added and the incubation continued for an additional 30 minutes. The cells were washed twice with chilled culture medium to remove the 4-HC and cultured in semisolid medium for the growth of hematopoietic CFCs as previously de~cribed.".'~ Cultures consisted of a-MEM supplemented with 1.2% methylcellulose (4000 CP, Fisher), 5 x mol/L 2-mercaptoethanol, 1% bovine serum albumin (Sigma Chemical Co, St Louis, MO), 30% FBS, mol/L methylprednisolone sodium succinate, 1 U/mL recombinant human TC-Epo, 50 U/mL IL-3, and 5% 5637-CM. Four to five replicate 1-mL cultures in 35-mm culture dishes (Costar, Cambridge, MA) for each experimental group were maintained in a 5% CO, humidified atmosphere at 37OC for up to 5 weeks. Colonies were scored on an inverted microscope at weekly intervals for 2 weeks and observed daily thereafter for the appearance of newly formed blast-cell colonies (Bl-CFC). From day 14 on, newly formed blast-cell colonies were picked from the culture dishes with a drawn-out pipette for morphology and replating studies. Cytospin-prepared slides were stained with Wright's stain to determine the morphology of colonies.
In one experiment Bl-CFCs from both IL-Iand TNFa-treated cultures were picked and replated in 24-well culture plates as previously described." Secondary colonies were scored on days 10 through 14 after replating.
Assay for leukemic blast progenitors. The effect of 4-HC on leukemic progenitors was examined using two different assay techniques. First a clonogenic assay was performed for the leukemic cell lines HL-60, K562, KG1, and primary peripheral-blood acute myelogenous leukemia (AML) blast cells. In this assay cells were cultured in a-MEM with 2% methylcellulose and 25% FBS. Five percent 5637-CM was added to all cultures of AML blasts and KGl cells. Triplicate 1-mL cultures with different cell concentrations ( lo3 to 10' cells of the leukemic cell lines and 5 x lo4 to 5 x IO5 AML blast cells) per plate were prepared for each experimental condition. Colonies (greater than 20 cells) were scored using an inverted microscope at day 7 of culture. In addition, blast cells obtained from the peripheral blood of an AML patient and capable of growing in a clonogenic assay were used for mixing experiments with post FH normal bone marrow cells. Post FH normal bone marrow with or without 17% AML cells were incubated for 20 hours with medium alone or 10 ng/mL IL-I + 5 ng/mL TNFa. 4-HC (65 pg/mL) was added for 30 minutes followed by washing the cells twice with cold medium. The cells were then cultured in the blast-cell colony assay as described above. Leukemic clusters (CFU-L) of more than 3 cells as well as normal colonies were scored weekly. CFU-L clusters were readily identified in situ and confirmed morphologically by Wright's stained cytospin-prepared slides. A second assay was used for the nonclonogenic leukemic cell lines DU.528 and KGla. After 4-HC treatment, 2 x 10' cells in doubling dilutions were cultured in triplicate in 96-well plates for 20 hours in 200 pL of medium.
[H]'-thymidine (1 pCi per well) was added and the incubation continued for another 4 hours. Cells were harvested using a microplate cell harvester (Cambridge Technology, Inc, Watertown, Blast-cell colony assay.
Replating studies.
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MA) and the incorporation of [HI3-thymidine recorded. Counts from control versus 4-HC-treated cultures were compared to determine whether IL-1 or TNFa offered any protection for leukemic cells from the chemotherapeutic agent 4-HC.
Supernatants from different bone marrows incubated with or without 100 ng/mL IL-1 for 20 hours were collected and assayed for TNFa levels using a TNFa enzyme-linked immunosorbent assay (ELISA) kit purchased from R&D Systems Inc (Minneapolis, MN). The assay is capable of detecting as low as 20 pg/mL TNFa.
Three to six replicates of each experiment were performed. Levels of significance for comparison between samples in each experiment were determined using the two-tailed Student's f test. The results are expressed as means f 1 SD of three to five plates per point.
TNFa ELISA.
Statistical analysis.
RESULTS
We have previously shown that preincubation for 20 hours with IL-1 before 4-HC treatment results in a significant increase in detectable single and multilineage colonies including B1-CFC.I7 In the present study we have compared the ability of T N F a and IL-1 preincubation for their ability to protect these early bone-marrow progenitors from 4-HC. Table 1 shows that preincubation of bone marrow cells with TNFa for 20 hours also protects a significant number of CFCs from 4-HC. In fact, T N F a a t a dose twofold lower than that of IL-1 was able to protect as many CFCs as IL-1 when measured a t day 21 of culture. To determine whether the increase of CFCs by TNFa was due to the preservation of a specific lineage, the morphology of colonies developing was determined. As shown previously17 for IL-1, a 20-hour incubation with IL-1 or T N F a in the absence of 4-HC treatment results in a nonsignificant variable effect on colony formation when compared with bone marrow incubated for 20 hours in the absence of IL-1 or TNFa. Table 1 also demonstrates that the type of colonies as well as the percentage of total CFCs protected by T N F a preincubation were very similar to the type of colonies seen with IL-1. About 4% of the CFCs were protected in the experiment shown in Table 1 . This probably represents a minimum recovery as calculated a t day 21 of culture, since more colonies continue to appear later in culture. In general the average recovery from three different experiments was 2% to 6%. Interestingly, higher doses of TNFa result in an absolute decrease in protection when compared to control. However, when compared with the colonies formed preA-HC, very little difference in the percentage recovery is seen. This is because the number of colonies formed pre-4-HC in the presence of increasing concentrations of T N F a also decreases. The type of colonies most affected appeared to be those containing erythroid cells (ie, BFU-E and CFU-Mix).
A similar inhibition by T N F a on CFCs has been previously r e p~r t e d , *~*~~-~~ suggesting that high doses of TNFa in our experiments might be toxic to early progenitor cells. The results of replating studies are shown in Table 2 and demonstrate that replating of Bl-CFC from either IL-1 or T N F a pretreated cultures gave similar results with the appearance of secondary colonies consisting of macrophages, granulocytes and macrophages, eosinophils, erythroid cells, mixed granulocyte/macrophage/erythroid/eosinophils, and undifferentiated blast colonies. The plating efficiencies for both were about 20%.
Since T N F a and IL-1 are capable of inducing each other,''-l4 we studied the protection effect of each cytokine for early progenitors from 4-HC in the presence of polyclonal rabbit antibodies to the other factor. Figure 1 shows the results of two representative experiments of five in which the IL-1 protective effect was completely abolished when bone marrow cells were preincubated with IL-1 in the presence of antibody to TNFa. The effect of T N F a antibodies was specific, since an equal volume of nonspecific rabbit IgG showed no effect, and no effects were seen when bone marrow cells were cultured with antibodies to TNFa before 4-HC treatment (data not shown). In contrast, preincubation of bone marrow cells with T N F a in the presence of antibody to IL-la and IL-l/3 resulted in decreased protection of early progenitors (Fig 2) . However, the protection was not completely abolished, as seen for IL-1 plus anti-TNFa (Fig 1) . Again, this effect of antibodies to IL-1 was specific, since controls performed with nonspecific rabbit IgG showed no effect.
In support of the above results, we measured the amount of endogenous TNFa present in supernatants obtained from bone marrow cultures incubated with 100 ng/mL IL-1 for 20 hours. Table 3 demonstrates the detection of a significant amount of TNFa as measured by ELISA in the supernatant of four different bone marrows incubated with IL-I. whereas little or no detectable TNFa activity was seen in the supernatants of three of these bone marrow incubated in the absence of I L-1.
Next we determined whether IL-l and TNFa would provide additive or synergistic protection for hematopoietic progenitor cells by incubating bone marrow cells with subop timal doses of IL-l and TNFa before 4-HC treatment. Table  4 demonstrates that combining IL-l and TNFa in the preincubation results in a synergistic increase in protection from 4-HC. The combination of IO ng/mL IL-l with 1 ng/mL TNFa results in 161 colonies at day 21 after 4-HC.
whereas IO ng/mL IL-l alone gave only a mean of four For personal use only. on October 3, 2017. by guest www.bloodjournal.org From were seen for K562, KG1, and DU.528 leukemic cells, although TNFa in the absence of 4-HC showed no effect (data not shown). Similarly, using 'H-TdR incorporation as a measure of cell proliferation, no protection was observed for TNFa or IL-1-BMCM when compared with control for KGla leukemic cells in the presence of increasing concentrations of 4-HC (Fig 4) . Once again TNFa and IL-1-BMCM alone significantly suppressed proliferation of KG 1 a cells when compared with the medium control (P < .025).
In addition, we tested the effects of 20 hours preincubation with IL-1, TNFa, or IL-1-BMCM before 4-HC on leukemic blast-cell colony formation obtained from patients with AML. Figure 5 shows the results of one of five representative The inhibition seen with TNFa was significant ( P < .025) when compared to the medium alone group.
AML patients studied. No effect on leukemic colony formation was seen with any of the materials tested. Increasing concentrations of 4-HC reduced the number of leukemic colonies scored, and prior incubation with IL-1, TNFa, or IL-1-BMCM showed no effect. Similar results were seen with the other four AML samples, which contained leukemic blasts from AML patients classified as M1, M2, and M5 using the FAB classification. Finally, leukemic blast cells from a sixth AML patient (classified as M3, HLA-DR-, TDT+) were used for mixing experiments with normal bone marrow. The mixed cell suspension contained 17% AML cells. Preincubation with 10 ng/mL IL-1 + 5 ng/mL TNFa protected normal colony formation when compared with medium alone whether the normal cells were cultured alone or mixed with leukemic cells (Table 5) . No leukemic cluster formation was observed after 4-HC treatment whether the leukemic cells were incubated in the presence of normal marrow with medium alone or IL-1 + TNFa (Table 5) . Similar protection from 4-HC of normal but not leukemic progenitors was observed when the mixture was preincubated with IL-1 or TNFa alone (data not shown). 
DISCUSSION
We have recently reported that 20 hours preincubation of normal human bone marrow cells with IL-1 can protect early progenitors from the lethal effects of high doses of 4-HC.17s26 Since IL-1 is known to induce the production of other cytokines from accessory cells and because we used a relatively crude population of cells in our previous experiments, we have investigated whether the protective effect observed with IL-1 is a direct effect of the IL-1 or an indirect effect through the production of other cytokines during the 20-hour incubation. We have previously reported that 20 hours preincubation with IL-6 or IL-3 did not protect human progenitor cells from 4-HC. In fact, use of these cytokines may increase the toxicity of 4-HC.26 In the present study we report that TNFa is also capable of protecting early he- matopoietic progenitor cells including replatable Bl-CFC from 4-HC (Table 1) . In general, TNFa was shown to be more potent than IL-1 in terms of protecting CFCs from 4-HC demonstrating protective effects with doses as low as 0.1 ng/mL, while IL-1 becomes unpredictable at low concentrations (ie, 10 ng/mL [Table 41 ). Higher doses of T N F a displayed significantly less protection (Table 1) . This decrease in protection for TNFa from 4-HC correlates with the T N F a inhibitory effect on CFCs reported p r e v i o~s l y~~*~"~'
and seen in this study following 20 hours incubation with T N F a (Table 1 ). All types of colonies were inhibited. In spite of this inhibitory effect, it is clear that a wide range of T N F a concentrations can be used to demonstrate significant protection from 4-HC (Tables 1 and 4) . Because of previous reports regarding the ability of IL-1 or TNFa to induce synthesis of each other,'&l4 we have investigated the following possibilities: (1) Is the IL-1 protection mediated by TNFa? (2) Does TNFa act indirectly via IL-1 production? or (3) Does T N F a act similarly and/or independently of IL-1 to provide protection against 4-HC toxicity? Our results show that antibodies to T N F a can abolish completely any protection seen by IL-1 (Fig 1) . Furthermore, a significant amount of T N F a was measured in the supernatants of bone marrow cells incubated for 20 hours with IL-1 while none was detected in the supernatants of bone marrow cells incubated in the absence of IL-1 (Table  3) . Although these results suggest that T N F a is the mediator of the protection provided by IL-1, the addition of IL-la and IL-lP antibodies to cells incubated with T N F a resulted in a significant decrease (P < .01) but not elimination of the T N F a protective effect (Fig 2) . Taken together these studies suggest that TNFa is necessary for the protection from 4-HC toxicity and that IL-1 interacts with TNFa to increase that protection. Support for this TNFa-IL-1 interaction comes from the results of our synergy studies. We have incubated bone marrow cells with low doses of combinations of IL-1 and T N F a prior to treatment with 4-HC. A synergistic effect on the number of CFCs recovered was observed when 0.1 to 1.0 ng/mL T N F a was mixed with 10 ng/mL IL-1 in three different experiments. Synergy between IL-1 and T N F a has been shown previously in different biologic a~tivities.~'-~' To date no synergistic effect between IL-1 and TNFa has been reported for the protection of hematopoietic cells from chemotherapeutic agents or in radioprotection. An additive effect was reported when both human T N F a and IL-1 were injected into mice 20 hours before lethal irradiati~n.'~ The mechanism for such synergy is not known. Because our target bone-marrow population is heterogeneous, we cannot rule out the possibility that the protection displayed by IL-1 and/or TNFa in the present study is indirect through the effects of these cytokines on accessory cells. Because IL-1 and T N F a do not share any apparent homology nor recognize the same cellular receptor, and since IL-1 down regulates the T N F a receptor49 as well as its own5' while T N F a has no influence on the IL-1 receptor, we speculate that the apparent synergy may result from similar effects on the postreceptor biochemical events that are not yet well defined. Another possible reason for the synergistic effect reported here is that TNFa and IL-1 may exert their effects at the level of transcription and stabilization of certain messenger RNAs (mRNAs) necessary for the protection from 4-HC. TNFa may increase the transcription rate of these putative mRNAs, and IL-1 may stabilize the message so that the end product is much higher in the presence of both factors, whereas TNFa alone will still provide protection and IL-1, in the absence of TNFa, will not.
The findings that TNFa and IL-1 are able to protect normal hematopoietic progenitor cells from 4-HC may have clinical significance if their protective effect is selective for normal cells when compared to malignant cells. We have previously reported the lack of protection for HL-60 and K562 leukemic cell lines from 4-HC when preincubated with IL-1 or IL-1-BMCM as well as the protection of normal but not HL-60 cells in mixing experiment^.'^^^'^^^ In the present study we compared the effects of 20 hours incubation with IL-1-BMCM, IL-1, or TNFa on the toxicity of 4-HC for human leukemic cell lines as well as AML blast cells. We have used both clonal assays and 'H-TdR uptake studies to measure proliferation. Our results demonstrate that IL-lP, IL-1-BMCM, or TNFa do not protect HL-60, K562, KGl, KGla, or DU.528 leukemic cell lines or any of five different AML blast cell populations from the lethal effects of 4-HC. In fact, significant increased toxicity to 4-HC was observed against HL-60 and KGla cells merely by the preincubation with IL-1-BMCM or TNFa. Furthermore, in a mixing experiment we have shown that IL-1 + TNFa can protect normal hematopoietic progenitors but not AML progenitors from the cytotoxicity of 4-HC. Among the AML blast-cell populations tested were at least four different FAB classes (Ml, M2, M3, and M5).
Tumoricidal activity against certain leukemic as well as solid tumors has been reported for IL-153-58 as well as
In addition, TNFa was reported to synergize with some chemotherapeutic agents in vivo and in vitro to kill tumor ~ells.6'-~~ A recent in vivo study showed that IL-1 protects mice from lethal irradiation but has no effect on tumors in the same animals.66 Thus far our results suggest that the protection by TNFa and IL-1 may be selective for normal hematopoietic progenitors and may mediate additional antitumor effects together with 4-HC in certain leukemias. Although IL-1 receptors were found on AML cells67 but not on HL-60, KGl, or K562 cells,68 TNFa receptors were found on AML as well as HL-60, KG1, KGla, and K562 cells.69s70 Since TNFa appears to be the dominant factor involved in the protection of normal progenitors, the selectivity by TNFa may be attributable to the phenomena of reverse signal transduction first described by Hatakeyama et al.71 These authors pointed out that growthfactor receptor interactions may induce the reverse effect on neoplastic cells when compared with normal cells. However, no direct experimental evidence is available for this using TNFa or IL-1, and alternative explanations are possible.
In summary, we have shown that TNFa may be the dominant cytokine responsible for the protection of early human progenitors from 4-HC. IL-1 was shown to synergize with TNFa and to enhance such protection. So far there is no evidence for similar protection for leukemic progenitors by TNFa and IL-1. The clinical significance of these findings is being tested in our laboratory using an animal model system. Other in vitro studies are also being conducted to investigate the possible mechanisms responsible for the protection of these primitive progenitors by TNFa and/or IL-1. 
